Back to search

National and Kapodistrian University of Athens

Ο ρόλος της φλοιοεπινεφριδιακής λειτουργικής εφεδρείας στην κλινική εκδήλωση και θεραπευτική αντιμετώπιση της ρευματοειδούς αρθρίτιδας

Abstract

dc:description

BackgroundRheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease affecting approximately 1% of the population and characterized by persistent joint inflammation and extra-articular manifestations. Treatment is based on a treat-to-target strategy using conventional synthetic (csDMARDs), biologic (bDMARDs), or targeted synthetic (tsDMARDs) disease-modifying antirheumatic drugs. Glucocorticoids are often employed as short-term «bridging therapy»; however, prolonged use remains frequent in up to 50% of patients and is associated with an increased risk of adverse effects, including tertiary adrenal insufficiency. In parallel, the “disproportion principle” suggests that endogenous cortisol production may be inadequate relative to the increased demands imposed by systemic inflammation in RA, even in the absence of previous corticosteroid exposure, indicating a relative impairment of adrenal function in, at least, some patients. Salivary cortisol represents a reliable marker of HPA axis function in chronic inflammatory conditions such as RA, as it reflects the free, biologically active fraction of cortisol and is not affected by variations in cortisol-binding globulin (CBG). This study aimed to systematically assess adrenal functional reserve in patients with active rheumatoid arthritis, and to determine whether the dynamics of diurnal salivary cortisol may serve as a potential prognostic biomarker for long-term therapeutic response and achievement of disease remission. Patients and Methods Thirty patients with active RA were recruited from the outpatient Rheumatology clinic of the General Hospital of Athens "Laiko" between 2021 and 2024. The total follow-up period was 24 months. Twenty-eight patients (24 females, mean age 56±10 years) completed the study. At baseline, 11 patients had moderately active disease and 17 had high disease activity (according to the DAS28-ESR). Thirteen patients were newly diagnosed and treatment-naïve, while 15 required treatment escalation in accordance with EULAR recommendations. Two age- and sex-matched control groups were also included: 28 healthy individuals and 28 patients with acute COVID-19 infection. Strict exclusion criteria were applied to ensure population homogeneity. For RA patients, clinical assessments and blood/saliva sampling were performed at baseline, 3, 6, and 24 months, whereas control participants were studied once at enrollment. Disease activity was evaluated using the DAS28-ESR and treatment response was categorized according to ACR/EULAR criteria (remission, minimal disease activity-MDA, non-response). Psychological burden was determined using the Perceived Stress Scale (PSS) and the Hamilton Depression Rating Scale, aiming to explore the potential impact of psychological factors on HPA axis function.Salivary cortisol was collected at four daily time points (08:00, 12:00, 18:00, and 22:00) to assess circadian rhythm and total daily output of the hormone. A disrupted cortisol circadian rhythm was defined as the absence of the expected diurnal decline at one or more time intervals. Plasma ACTH, total serum cortisol, and DHEAS levels were measured using immunoassays. ResultsAt baseline, RA patients showed comparable salivary cortisol levels to healthy controls in the morning, noon, and evening time points, but significantly higher nocturnal values (4.0±3.5 vs. 1.9±0.8 nmol/L, p=0.005). Compared to patients with COVID-19 infection, RA patients exhibited significantly reduced total diurnal cortisol production (assessed as AUC), despite similar levels of systemic inflammation. A disrupted diurnal cortisol rhythm was more frequent in RA patients (53.6%) than in healthy controls (14.3%). Low baseline morning salivary cortisol levels (<13.9 nmol/L) predicted failure to achieve minimal disease activity (MDA) at 6 months, with 75% sensitivity and 92% specificity. Furthermore, higher total daily salivary cortisol production (AUC ≥81.3) predicted remission at 24 months with 65% sensitivity and 86% specificity. Patients who did not achieve MDA or remission demonstrated a significantly lower serum cortisol/ACTH ratio. Conclusion Overall, the findings support the concept that reduced adrenocortical functional reserve may contribute to the pathophysiology of RA and influence long-term clinical outcomes. Moreover, salivary cortisol emerges as a reliable, non-invasive biomarker with potential prognostic utility for predicting treatment response and guiding individualized therapeutic strategies.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Filippa, Maria
  • Φίλιππα, Μαρία

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/61277

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Filippa, Maria; Φίλιππα, Μαρία. Ο ρόλος της φλοιοεπινεφριδιακής λειτουργικής εφεδρείας στην κλινική εκδήλωση και θεραπευτική αντιμετώπιση της ρευματοειδούς αρθρίτιδας. National and Kapodistrian University of Athens, 2026. http://hdl.handle.net/10442/hedi/61277